A randomized, placebo controlled, parallel-group, multicenter clinical trial to evaluate the preventive effect on acute exacerbation of chronic obstructive pulmonary disease (COPD) with Carbocisteine (1500mg/day)

A randomized, placebo controlled, parallel-group, multicenter clinical trial to evaluate the preventive effect on acute exacerbation of chronic obstructive pulmonary disease (COPD) with Carbocisteine (1500mg/day) - Preventive effect on acute exacerbation of chronic obstructive pulmonary disease with Carbocisteine (PEACE Study)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000233

Enrollment

720

Registered

2006-12-01

Start date

2005-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Interventions

Carbocisteine group 1500mg/day (13 months) Placebo group (13 months)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Stable COPD patient (Stage II-IV) 2. Between 40 and 80 years 3. Out-patient 4. Written informed consent 5. At least 2 exacerbations in the previous 2 years

Exclusion criteria

Exclusion criteria: 1. Intolerance for Carbocisteine 2. Use of mucolytic agents within one month prior to beginning of the study 3. Use of antibiotics at the beginning of the study 4. Bronchiectasis, pneumonia, interstitial lung disease, tuberculosis 5. Carcinoma 6. Previous lung transplant or lung volume reduction surgery 7. Pregnant or breastfeeding 8. Attendance in the other study within 3 months prior to the beginning of the study 9. Underlying severe disease

Design outcomes

Primary

Measure	Time frame
Frequency of exacerbations	—

Countries

Asia(except Japan)

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026